MedTrace Logo

Use of Teriparatide to Accelerate Fracture Healing

NCT00594906 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-12-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effect of the drug teriparatide to the effect of placebo on pelvic fracture healing.

Conditions

  • Pelvic Fracture

Interventions

DRUG

Teriparatide

Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)

DRUG

Placebo

Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)

Sponsors & Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Rochester

    lead OTHER

Principal Investigators

  • J.Edward Puzas, PhD · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00594906 on ClinicalTrials.gov